Stockreport

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting [Yahoo! Finance]

OKYO Pharma Limited - Ordinary Shares  (OKYO) 
PDF investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, [Read more]